Every drug formulation is unique, just like every patient is too. Particularly high-potency medicines that are entering the market have exacting pharma packaging needs to ensure drug stability. With every drug requiring specific packaging features, pharma companies are looking for a concept that combines established packaging standards and a modern approach.
Multiple needs, one solution
In order to meet the various exacting demands of sensitive drugs and drugs with low filling volumes, SCHOTT developed a modular vial concept known as SCHOTT EVERIC™. Manufactured from an improved FIOLAX® borosilicate glass tubing, namely FIOLAX® CHR (controlled hydrolytic resistance), the ultra-pure vials offer a packaging solution that serves individual drug and patient needs.
Unmatched drug stability
Manufactured according to the company’s approved delamination controlled forming process, EVERIC™ pure vials feature a high chemical stability and homogeneous surface near the bottom heel area. A reduction of leachables by 68% makes the vials particularly suitable for biologics with low-filling volumes, while ensuring that delamination is under full control. Moreover, by keeping the glass composition untouched, no costly re-registration is needed when replacing conventional tubular type-I glass vials for already marketed drugs with EVERIC™ pure.
EVERIC™ strong vials stand for optimized container strength, which is achieved by designing geometries within the ISO tolerances. With the help of computer simulation, the vial's handling and contact points in the heel and shoulder area are improved to better withstand axial and side pressure. In fact, the vials demonstrate a higher strength on side compression by 210%. The optimized geometries further eliminate inherent stress in the glass.
Smoother line operations
EVERIC™ smooth vials feature an outer coating to additionally protect the glass surface from flaws during the entire process. Cosmetic defects are subsequently reduced by 98%. The transparent outer coating on the bottom and tubular part of the containers create a low friction surface while maintaining the optimized container strength. The result: An improvement of the coefficient of friction (CoF) by 80 % for a smooth container flow to prevent vials from climbing or sticking.
The story behind EVERIC™
Dr. Robert Frost, Dr. Florian Maurer and Stephanie Mangold from the development team present key features from EVERIC™ and share insights about why drugs of the 21st century benefit from a modular primary packaging set-up.
Health plays a vital role in society and as novel drugs and treatment options are being developed, requirements for the drug packaging will only become more complex. Whether it is to protect the drug formulation or to improve the patient experience, an extended EVERIC™ vial portfolio including, for example, an inner coating for enhanced drug stability will ensure that all needs – both from the drug and the patient – are covered.